Back

An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a Danish healthcare perspective

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: ablation 2 Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Jason Andrade

Vancouver General Hospital, Vancouver (Canada)

6 More presentations in this session

Presentation thumbnail
A multicenter evaluation of repeat ablation for atrial fibrillation in patients with isolated pulmonary veins: a Netherlands Heart Registration study
Mr F. Magni (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Durability of pulmonary vein isolation with pulsed field ablation compared to radiofrequency ablation in patients with persistent atrial fibrillation: results from a prospective remapping study
Doctor O. Galuszka (Lucerne, CH)
Abstract Slides Video
Presentation thumbnail
Left atrial wall thickness measured by a machine learning method predicts AF recurrence after pulmonary vein isolation
Doctor D. Gomes (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Pulsed-field vs. cryo-balloon based pulmonary vein isolation: does reduced autonomic modulation effect freedom of atrial fibrillation?
Doctor M. Lemoine (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Procedural characteristics, details on epicardial mapping-based lesion transmurality, and long-term success of posterior wall isolation with a pentaspline pulsed field ablation device
Doctor D. Della Rocca (Brussels, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: ablation 2
Video

The Event

Event poster

EHRA 2024

7 April - 9 April 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources